Chiasma, Inc. (NASDAQ:CHMA) Files An 8-K Results of Operations and Financial Condition

Item2.02

On March16, 2017, Chiasma, Inc. (the Company) issued a press
release announcing its financial results for the quarter ended
December31, 2016 and providing a business update. The full text
of the press release is furnished as Exhibit 99.1 hereto and
incorporated herein by reference.

The information under this Item2.02, including Exhibit 99.1
attached hereto, is intended to be furnished and shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934, as amended (the Exchange Act), or otherwise subject
to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such filing.

About Chiasma, Inc. (NASDAQ:CHMA)

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company’s TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.

Chiasma, Inc. (NASDAQ:CHMA) Recent Trading Information

Chiasma, Inc. (NASDAQ:CHMA) closed its last trading session up +0.05 at 1.70 with 36,630 shares trading hands.